Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Extended Survival Most Wanted by Breast Cancer Patients: Survey
April 26, 2010
- Korosho Calls For Enhancement of Compliance
April 26, 2010
- MSD to Boost Sales to ¥500 Bil. Within 5 Years
April 26, 2010
- Mr Mitani Proposes Review of PMDA's NDA Review System
April 26, 2010
- US Pharm. Market Up 5.1% to US$300 Bil. in 2009: IMS Health
April 26, 2010
- 23% of Pharmacies Aim at Generic Usage Rate of Over 30%
April 26, 2010
- MTPC Ordered to Suspend Business for 25 Days
April 26, 2010
- Taiyo Puts End to “One-Stop Generic Company”Policy
April 26, 2010
- Symyx to Introduce ELE to Japanese Companies
April 26, 2010
- Ethical Drugs Sales Up 2.3% in Jan., Flat in Feb.: Crecon
April 26, 2010
- Mr Chofuku Urges Makers to Explain Meaning of New Premium to Med. Institutions
April 19, 2010
- Gov't Considers Health/Nursing Care, Drugs as Growth Drivers: Mr Nagatsuma
April 19, 2010
- Korosho to Encourage Switching of Ethical Drugs to OTC Status: Mr Nagatsuma
April 19, 2010
- Remicade Ranked No.1 on HP Market
April 19, 2010
- Cautious Discussions Necessary on Lifting of Ban on Kongo Shinryo: Mr Nagatsuma
April 19, 2010
- JACDS Calls For Continued Discussions on Online Sale of Drugs
April 19, 2010
- Taizhou City Invites Japanese Pharmas to Invest
April 19, 2010
- Arixtra Applied for Treatment of Acute DVT, PE: GSK
April 19, 2010
- JPA Supports Court Decision on Online Sale of Drugs: VP Idei
April 19, 2010
- Nippon Shinyaku Licenses Once-Daily Tramadol from Labopharm
April 19, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…